User profiles for Jordan T. Said
 | Jordan Taylor Said, MDBrigham and Women's Hospital; Harvard Medical School Verified email at bwh.harvard.edu Cited by 488 |
Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer
…, EB Li, NJ Polyakov, GE Molina, JT Said… - JAMA …, 2021 - jamanetwork.com
Importance Cutaneous immune-related adverse events (cirAEs) are some of the earliest
toxic reactions to emerge following immune-checkpoint inhibitor (ICI) initiation. As an early …
toxic reactions to emerge following immune-checkpoint inhibitor (ICI) initiation. As an early …
Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors
Importance De novo bullous pemphigoid (BP) is a rare immune-mediated adverse event from
immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of the …
immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of the …
[PDF][PDF] Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor–induced bullous pemphigoid
JT Said, J Talia, E Wei, A Mostaghimi… - Journal of the American …, 2023 - Elsevier
Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a rare antibody-mediated
skin 60 toxicity, reportedly affecting up to 1.0% of ICI-treated patients. 1 This dermatologic …
skin 60 toxicity, reportedly affecting up to 1.0% of ICI-treated patients. 1 This dermatologic …
[HTML][HTML] 3D Printed frames to enable reuse and improve the fit of N95 and KN95 respirators
Background In response to supply shortages caused by the COVID-19 pandemic, N95
filtering facepiece respirators (FFRs or “masks”), which are typically single-use devices in …
filtering facepiece respirators (FFRs or “masks”), which are typically single-use devices in …
Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana …
IR Plumptre, JT Said, T Sun, C Larocca… - Leukemia & …, 2022 - Taylor & Francis
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD)
was reclassified in 2016 as a rare benign entity with an excellent prognosis, yet its clinical …
was reclassified in 2016 as a rare benign entity with an excellent prognosis, yet its clinical …
Use of an educational video to improve transgender health care knowledge
CE Guss, S Dahlberg, JT Said, J Addison… - Clinical …, 2022 - journals.sagepub.com
Methods An 8-minute educational video was developed to teach essential topics in TNB
health (see supplemental video: https://www. dropbox. com/s/owbo2agtxsoyu90/BCH_Stepping…
health (see supplemental video: https://www. dropbox. com/s/owbo2agtxsoyu90/BCH_Stepping…
Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder in children: A case report and review of the literature
IR Plumptre, JT Said, J Sheu Song… - Pediatric Blood & …, 2022 - Wiley Online Library
Primary cutaneous CD4 + small/medium T‐cell lymphoproliferative disorder (PCSM‐TCLPD)
is a rare benign lymphoproliferative disorder, recently redefined by the 2016 World Health …
is a rare benign lymphoproliferative disorder, recently redefined by the 2016 World Health …
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors
Background Cutaneous immune-related adverse events (irAEs) are the most common irAEs
caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and …
caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and …
[HTML][HTML] Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders
Inhibition of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) has been
utilized as a treatment strategy for a variety of immune-mediated inflammatory disorders (IMID), …
utilized as a treatment strategy for a variety of immune-mediated inflammatory disorders (IMID), …
Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events
LL Thompson, JT Said, EB Li, J Yoon… - Supportive Care in …, 2022 - Springer
Purpose Supportive oncodermatology has been shown to improve several aspects of care
for patients with cancer, but research showing improved diagnostic accuracy as a benefit of …
for patients with cancer, but research showing improved diagnostic accuracy as a benefit of …